Market Cap 29.39M
Revenue (ttm) 10,000.00
Net Income (ttm) -4.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -40,500.00%
Debt to Equity Ratio 0.00
Volume 112,400
Avg Vol 174,510
Day's Range N/A - N/A
Shares Out 13.48M
Stochastic %K 83%
Beta 1.14
Analysts Strong Sell
Price Target $10.75

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
slick75
slick75 Oct. 4 at 12:49 AM
$DARE Larc1
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Oct. 3 at 7:16 PM
$DARE I don’t see any short-term fundamental catalysts that could trigger a breakout to the upside. There’s a significant amount of ”trapped” volume overhead, likely waiting to exit their positions. Market makers have gradually trended the price higher to a level where a reversal could soon occur. I’m waiting for a breakdown toward the long-term trendline. The 1.50 level appears to be a realistic target. In my opinion.
1 · Reply
GolfPro999
GolfPro999 Oct. 3 at 5:23 PM
$DARE new website https://darebioscience.com
1 · Reply
Hudafin
Hudafin Oct. 2 at 7:41 PM
0 · Reply
Teo_j
Teo_j Oct. 2 at 10:19 AM
$DARE you need massive news
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Oct. 1 at 6:20 PM
$DARE Sold my last shares today.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 30 at 8:56 PM
$DARE I previously made a comparison with $KALA in terms of OBV. The disappointing performance of $KALA clearly illustrates the risks associated with biotech companies facing binary events. What concerns me about $DARE is the lack of communication regarding the expected completion date of the Phase 3 trial. In fact, in their latest corporate presentation, they even removed Ovarprene from the list of upcoming catalysts for 2026 — which raises the question: why? If that’s no longer a driver, what will move the price in 2026? It will take time before we know whether sildenafil turns out to be a success.
1 · Reply
Ceri78
Ceri78 Sep. 30 at 3:38 PM
$DARE seeping company, sleeping CEO, sleeping employees…wtf!
0 · Reply
TheManUpstairs
TheManUpstairs Sep. 30 at 3:14 PM
$DARE me @ 2,1
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 26 at 8:17 PM
$DARE Unfortunately, there is currently a clear lack of buying interest in Dare, which became evident yesterday. Should a press release be issued, it’s not uncommon for long-term holders to sell initially, only to re-enter at lower levels from those who have lost conviction. As the stock is highly illiquid, the risk of capital being locked into a stagnant, high-volatility position is too great — which is why I’ve chosen to reduce my exposure. $XBI is strong but Dare is not. That said, my previous analyses remain unchanged. Market timing remains difficult, and maintaining a long-term position is still a valid strategy.
0 · Reply
Latest News on DARE
Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:48 PM EDT - 7 weeks ago

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript


Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 1:09 PM EDT - 2 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump


Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:13 PM EDT - 5 months ago

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript


Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:14 PM EDT - 6 months ago

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript


Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:03 PM EST - 11 months ago

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript


Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split


Daré Bioscience to Participate in Three November Conferences

Nov 6, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience to Participate in Three November Conferences


slick75
slick75 Oct. 4 at 12:49 AM
$DARE Larc1
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Oct. 3 at 7:16 PM
$DARE I don’t see any short-term fundamental catalysts that could trigger a breakout to the upside. There’s a significant amount of ”trapped” volume overhead, likely waiting to exit their positions. Market makers have gradually trended the price higher to a level where a reversal could soon occur. I’m waiting for a breakdown toward the long-term trendline. The 1.50 level appears to be a realistic target. In my opinion.
1 · Reply
GolfPro999
GolfPro999 Oct. 3 at 5:23 PM
$DARE new website https://darebioscience.com
1 · Reply
Hudafin
Hudafin Oct. 2 at 7:41 PM
0 · Reply
Teo_j
Teo_j Oct. 2 at 10:19 AM
$DARE you need massive news
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Oct. 1 at 6:20 PM
$DARE Sold my last shares today.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 30 at 8:56 PM
$DARE I previously made a comparison with $KALA in terms of OBV. The disappointing performance of $KALA clearly illustrates the risks associated with biotech companies facing binary events. What concerns me about $DARE is the lack of communication regarding the expected completion date of the Phase 3 trial. In fact, in their latest corporate presentation, they even removed Ovarprene from the list of upcoming catalysts for 2026 — which raises the question: why? If that’s no longer a driver, what will move the price in 2026? It will take time before we know whether sildenafil turns out to be a success.
1 · Reply
Ceri78
Ceri78 Sep. 30 at 3:38 PM
$DARE seeping company, sleeping CEO, sleeping employees…wtf!
0 · Reply
TheManUpstairs
TheManUpstairs Sep. 30 at 3:14 PM
$DARE me @ 2,1
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 26 at 8:17 PM
$DARE Unfortunately, there is currently a clear lack of buying interest in Dare, which became evident yesterday. Should a press release be issued, it’s not uncommon for long-term holders to sell initially, only to re-enter at lower levels from those who have lost conviction. As the stock is highly illiquid, the risk of capital being locked into a stagnant, high-volatility position is too great — which is why I’ve chosen to reduce my exposure. $XBI is strong but Dare is not. That said, my previous analyses remain unchanged. Market timing remains difficult, and maintaining a long-term position is still a valid strategy.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 24 at 12:15 PM
$DARE https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-receive-499000-support-preeclampsia-research
1 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 24 at 11:27 AM
$DARE I have a feeling that it’s primarily well-capitalized retail investors who are shorting Dare. If that’s the case, we could see a minor squeeze—even though the current short interest isn’t alarmingly high. This could be triggered by potential margin calls in the event of a sudden price spike. Short sellers have been largely correct about Dare for years and have profited handsomely. However, many got burned in July when the price surged sharply. New short positions were established during that time, and around 200k shares remain short today, after approximately 900k shares were covered. Those who sold their shares to short sellers now represent latent buying power. Should FOMO kick in, many of these former shareholders may jump back in, driving further demand. Just my opinion—not financial advice.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 23 at 6:51 PM
$DARE OBV (On-Balance Volume) often acts as an early indicator when institutional investors begin to accumulate long-term positions well ahead of a revaluation. A relevant example is $KALA, which saw a notable volume spike in late 2022/early 2023. Following that spike, the share price declined steadily—but has surged significantly in 2025, rising from $2.92 (April) to $20.60 (September). Interestingly, Baker Bros disclosed a 10% stake shortly after the initial volume surge in late 2022. Since then, they have doubled their position, suggesting strong institutional conviction despite the temporary price weakness. Kala demonstrate how companies can undergo rapid revaluations in anticipation of key catalysts. When the outcome of such a trigger is positive, the valuation can quickly reset at a substantially higher level. The breakout in Dare OBV may suggest that institutional investors have started to position themselves.
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 23 at 11:15 AM
$DARE XOMA invested in XACIATO based on its future commercial potential, with Daré entitled to a share once XOMA reaches a certain return. A new partnership between Organon and Evvy could help accelerate XACIATO’s adoption by allowing women diagnosed with bacterial vaginosis at home to get prescriptions directly through Evvy, potentially enabling same-day treatment without a clinic visit. https://www.futurefemhealth.com/p/organon-and-evvy-team-up-to-broaden
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 23 at 10:44 AM
$DARE DARE-PTB1 is an investigational intravaginal ring designed to deliver bio-identical progesterone continuously for up to 14 days, aimed at preventing preterm birth. According to a September update on ClinicalTrials.gov, the study is expected to begin in November, with primary completion anticipated as early as January 2026. https://cdek.pharmacy.purdue.edu/trial/NCT06668896/ The trial is supported by a $2 million grant from the NICHD (Eunice Kennedy Shriver National Institute of Child Health and Human Development). https://www.nasdaq.com/press-release/dare-bioscience-reports-full-year-2024-financial-results-and-provides-company-update
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 23 at 9:48 AM
$DARE I return briefly to the potential valuation indications for a company developing a product in support of women’s sexual empowerment. https://vellabio.com/?srsltid=AfmBOopik_Uv7So_nhFGfyUVF6fm7M-Fjq2xegS_A2O0lGcnE77AcIBj Vella Bioscience is a femtech company committed to advancing scientific innovation in support of women’s sexual empowerment. The company closed a $7 million Seed II funding round, led by Aaron Fleck & Associates. The round was significantly oversubscribed, bringing Vella Bioscience’s post-money valuation to over $50 million. https://beautymatter.com/articles/vella-bioscience-secures-7-million-in-seed-ii-funding
0 · Reply
GolfPro999
GolfPro999 Sep. 23 at 2:28 AM
$DARE our time is coming…
0 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 20 at 7:30 PM
$DARE Technical and Fundamental Signals in Focus The stock is showing some positive technical signals on the monthly chart: ✅ OBV (On-Balance Volume) breaking out – volume leads price ✅ MACD turning upwards ✅ PVO strengthening momentum The breakout in OBV may suggest that institutional investors have started to position themselves. This could indicate that “smart money” is anticipating a larger move ahead. While the price has been consolidating, something is happening beneath the surface. OBV is based on the principle that volume precedes price, meaning volume shifts often occur before significant price movements.
1 · Reply
BuyAndHoldStocks
BuyAndHoldStocks Sep. 20 at 7:16 PM
$DARE Comparison of Aspargo Labs, Inc. (AAGO) and Dare Bioscience: Potential Valuation Insight Overview: Recent information on Aspargo Labs, Inc. (AAGO) offers a useful benchmark for evaluating companies developing sildenafil-based combination products via the FDA’s 505(b)(2) regulatory pathway — the same route being used by Dare Bioscience. While both companies share regulatory similarities, Dare’s broader, more advanced pipeline suggests a higher valuation potential. ⸻ Key Regulatory Context: 505(b)(2) Pathway From Aspargo’s SEC filings: “We are seeking FDA approval for Sildenafil Oral Suspension…as a drug/device combination product…using the 505(b)(2) pathway.” This pathway provides an expedited route to market for modifications of previously approved drugs — such as new dosage forms or delivery methods. ⸻
1 · Reply
alotobeer
alotobeer Sep. 20 at 12:57 PM
0 · Reply
Janniss
Janniss Sep. 18 at 8:55 PM
$BREA Well that was a nice rally, i just feel sorry for those who got late in the game 😬 But if you want to be early next time $DARE is the way, early October–November (High probability) • Pre-launch news for DARE to PLAY™ Sildenafil Cream • Supply chain, compounding, physician engagement updates. • Expect press release before launch in Q4, dont be the one who buys on top and sell in loss, The best time to get in at $DARE is NOW!
0 · Reply
Janniss
Janniss Sep. 18 at 8:38 PM
$ETNB Good rally, but nothing is left here after today. in the other side though $DARE Early October–November 2025 (High probability) • Pre-launch news for DARE to PLAY™ Sildenafil Cream • Supply chain, compounding, physician engagement updates. • Expect press release before launch in Q4. This one went like 270% up in just a day last time we gad good news, and can easy happen again, the time is now.
0 · Reply